Johnson & Johnson (JNJ) Non-Current Debt (2009 - 2026)

Johnson & Johnson's (JNJ) quarterly Non-Current Debt came in at $37.5 billion in Q1 2026, down 2.16% year-on-year from $38.4 billion in Q1 2025, and down 4.85% quarter-over-quarter from $39.4 billion in Q4 2025.

Johnson & Johnson (JNJ) Non-Current Debt (2009 - 2026) Analysis & Trends

Johnson & Johnson has disclosed Non-Current Debt across 18 years of filings, most recently posting $37.5 billion for Q1 2026.

  • Non-Current Debt for Q1 2026 came in at $37.5 billion, down 2.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $37.5 billion (down 2.16% YoY), and the FY2025 annual result was $39.4 billion, up 28.67% from the prior year.
  • Non-Current Debt came in at $37.5 billion for Q1 2026 at Johnson & Johnson, down from $39.4 billion in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $39.4 billion in Q4 2025 to a low of $25.1 billion in Q1 2024.
  • The 5-year median for Non-Current Debt is $31.0 billion (2024), against an average of $31.9 billion.
  • Across the five-year window, Non-Current Debt decreased 28.19% in 2024 and jumped 52.92% in 2025, its largest moves.
  • Johnson & Johnson's Non-Current Debt stood at $27.6 billion in 2022, then slipped by 6.24% to $25.9 billion in 2023, then increased by 18.43% to $30.7 billion in 2024, then advanced by 28.67% to $39.4 billion in 2025, then declined by 4.85% to $37.5 billion in 2026.
  • The last three Non-Current Debt figures came in at $37.5 billion (Q1 2026), $39.4 billion (Q4 2025), and $39.4 billion (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn -18.89 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 39.37 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 37.53 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 64.53 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn 46.67 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 51.89 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 20.86 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 60.57 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 42.15 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn - -

Historic Data

Download Data
DateValue
Mar 29, 2026 37.53 Bn
Mar 29, 2026 37.53 Bn
Dec 28, 2025 39.44 Bn
Dec 28, 2025 39.44 Bn
Sep 28, 2025 39.41 Bn
Sep 28, 2025 39.41 Bn
Jun 29, 2025 39.24 Bn
Jun 29, 2025 39.24 Bn
Mar 30, 2025 38.36 Bn
Mar 30, 2025 38.36 Bn
Dec 29, 2024 30.65 Bn
Dec 29, 2024 30.65 Bn
Sep 29, 2024 31.29 Bn
Sep 29, 2024 31.29 Bn
Jun 30, 2024 31.64 Bn
Jun 30, 2024 31.64 Bn
Mar 31, 2024 25.08 Bn
Mar 31, 2024 25.08 Bn
Dec 31, 2023 25.88 Bn
Dec 31, 2023 25.88 Bn